TRKB OR TRKC AGONIST COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC CONDITIONS

(19)

(11)

EP 3 328 898 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	10.04.2024 Bulletin 2024/15

(45)	Mention of the grant of the patent:
	06.03.2024 Bulletin 2024/10

(21)	Application number: 16831377.3

(22)	Date of filing: 28.07.2016

(51)

International Patent Classification (IPC):

A61K 39/395^(2006.01)
A61P 27/16^(2006.01)

C07K 16/28^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	A61K 38/185; A61K 39/39591; C07K 2317/94; C07K 16/2863; C07K 2317/75; A61K 2039/505; A61P 25/00; A61P 27/16; A61P 7/10; A61P 9/00

(86)	International application number:
	PCT/US2016/044574

(87)	International publication number:
	WO 2017/019907 (02.02.2017 Gazette 2017/05)

(54)	TRKB OR TRKC AGONIST COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC CONDITIONS TRKB- ODER TRKC-AGONISTEN-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG VON ERKRANKUNGEN DES OHRS COMPOSITIONS D'AGONISTE TRKB OU TRKC ET MÉTHODES DE TRAITEMENT DE TROUBLES OTIQUES

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

28.07.2015 US 201562198065 P

(43)	Date of publication of application:
	06.06.2018 Bulletin 2018/23

(73)	Proprietor: 6452728 Canada Corp.
	Montreal, QC H4A3L8 (CA)

(72)	Inventors:
	SARAGOVI, Horacio Uri Montreal, Québec H4A 3L8 (CA) PIU, Fabrice San Diego, California 92131 (US) FOSTER, Alan San Diego, California 92127 (US) BLACK, KristenAnn Solana Beach, California 92075 (US)

(74)	Representative: HGF
	HGF Limited 1 City Walk Leeds LS11 9DX Leeds LS11 9DX (GB)

(56)

References cited: :

WO-A2-2009/132050
WO-A2-2010/011609
US-A1- 2002 039 995
US-A1- 2014 004 119

WO-A2-2009/132050
WO-A2-2010/086828
US-A1- 2002 176 859
US-B2- 8 030 297

RUDOLF GLUECKERT ET AL: "Nanoparticle mediated drug delivery of rolipram to tyrosine kinase B positive cells in the inner ear with targeting peptides and agonistic antibodies", FRONTIERS IN AGING NEUROSCIENCE, vol. 7, 19 May 2015 (2015-05-19), pages 1-18, XP055530403, DOI: 10.3389/fnagi.2015.00071
AMELIA TORCELLO-GÓMEZ ET AL: "Adsorption of antibody onto Pluronic F68-covered nanoparticles: link with surface properties", SOFT MATTER, vol. 7, no. 18, 1 January 2011 (2011-01-01), pages 8450-8461, ISSN: 1744-683X, DOI: 10.1039/c1sm05570d

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).